Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
2013
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Computational Radiomics System to Decode the Radiographic Phenotype
2017 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Cancer statistics, 2022
2022 Standout
Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer
2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
2014
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
2009
Gastric cancer
2016 Standout
Cancer Statistics, 2021
2021 Standout
Ancient Origin of cGAS-STING Reveals Mechanism of Universal 2′,3′ cGAMP Signaling
2015 StandoutNobel
Establishing the Diagnosis of Lung Cancer
2013 Standout
Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
2013
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
PARP inhibitor combination therapy
2016
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2013
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
2015 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
2015
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
2010
Machine learning applications in cancer prognosis and prediction
2014 Standout
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
2009
Molecular mechanisms of cisplatin resistance
2011 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Antibody therapy of cancer
2012 Standout
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
2016
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
2009
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
2014
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
2017 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
2010
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
2012
Photodynamic therapy of cancer: An update
2011 Standout
Treatment of Stage IV Non-small Cell Lung Cancer
2013
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
2014 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
ROS and the DNA damage response in cancer
2018 Standout
The current status of targeted therapy for non‐small cell lung cancer
2009
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Artificial intelligence in radiology
2018 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
2010
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
2012
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC
2016
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
2012
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
2011
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction
2018 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
The Potential of Radiomic-Based Phenotyping in Precision Medicine
2016
Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer
2022 StandoutNobel
Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer
2012
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
2010
Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care
2011
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
2019
Necitumumab for the Treatment of Advanced Non-Small-Cell Lung Cancer
2018
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
2016 Standout
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
2014 Standout
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Works of Thomas Goddemeier being referenced
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
2014
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
2009
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
2010
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
2013